Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer
April 23 2019 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced the appointment of
Eric Kimble as Chief Commercial Officer. Mr. Kimble will be
responsible for the design and execution of a global commercial
strategy, including sales and marketing operations.
“We are very pleased to welcome Eric to our team
as we prepare to commercialize our lead clinical assets, ETX2514SUL
and zoliflodacin,” commented Manos Perros, Chief Executive Officer
of Entasis Therapeutics. “Entasis has reached a pivotal moment with
the recent launch of ATTACK, our Phase 3 clinical trial of
ETX2514SUL, and the planned launch of the Phase 3 clinical trial of
zoliflodacin in collaboration with our partner, the Global
Antibiotic Research and Development Partnership (GARDP) in
mid-2019. Eric’s commercial leadership experience with CUBICIN®, as
well as his customer-centric focus will drive a commercial
organization that places patients and providers at the center of
everything we do at Entasis.”
Mr. Kimble is an accomplished life sciences
executive with over 25 years of experience in sales, marketing and
commercialization. Before joining Entasis Therapeutics as an
employee, he worked on a consulting basis for the Company, as well
as for several other antibiotic companies. Previously, he
held various leadership roles at Cubist Pharmaceuticals, including
VP of Sales and Marketing during the accelerated growth phase of
CUBICIN, and VP of Program and Portfolio Management. Mr. Kimble has
held various sales and marketing positions at Biogen Inc. and Merck
& Co. and began his career in management consulting at Arthur
D. Little, Inc. Mr. Kimble earned his M.B.A. from Harvard
University and his bachelor’s degree as a double major in English
Literature and Business Economics from Brown University.
“The Centers for Disease Control has identified
multidrug-resistant Acinetobacter, carbapenem-resistant
Enterobacteriaceae (CRE), and drug-resistant Neisseria gonorrhoeae
as three of the bacterial pathogens that pose dangerous antibiotic
resistance threats in the United States,” said Mr. Kimble.
“Entasis’s pipeline addresses all three of these specific
pathogens, and I welcome the challenge of commercializing
antibiotics in an environment that demands value for patients and
the providers that serve them.”
CUBICIN® is a registered trademark of Merck
Sharp & Dohme Corp.
About Entasis
Entasis is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel antibacterial products to treat serious infections caused
by multidrug-resistant Gram-negative bacteria. Entasis’
targeted-design platform has produced a pipeline of product
candidates, including ETX2514SUL (targeting A. baumannii
infections), zoliflodacin (targeting Neisseria gonorrhoeae), and
ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information, visit
www.entasistx.com.
Entasis Company Contact Kyle Dow Entasis
Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactLee RothThe Ruth
Group646-536-7012lroth@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024